K//@daz88888888:$AC Immune SA(ACIU)$AC Immune SA (ACIU) Updatesnewsletter.AC Immune (NASDAQ:ACIU - Get Rating) last released its quarterly earnings results on Thursday, July 28th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01.A number of other research firms have also issued reports on ACIU. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of AC Immune in a report on Friday, June 17th. StockNews.com started coverage on AC Immune in a report on Wednesday, July 27th. They issued a "sell" rating for the company.AC Immune Stock Up 4.4 %ACIU opened at $3.42 on Thursday. AC Immune has a 52 week low of $2.06 and a 52 week high of $12.61. The business has a fifty day simple moving average of $3.27 and a 200-day simple moving average of $3.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.28 and a current ratio of 13.28.Institutional Trading of AC ImmuneA number of hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in AC Immune by 2.3% in the first quarter. Renaissance Technologies LLC now owns 452,490 shares of the company's stock valued at $1,810,000 after buying an additional 10,300 shares in the last quarter. Lombard Odier Asset Management Switzerland SA raised its stake in AC Immune by 9.2% in the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 348,196 shares of the company's stock valued at $1,724,000 after buying an additional 29,451 shares in the last quarter. BlackRock Inc. raised its stake in AC Immune by 1.6% in the first quarter. BlackRock Inc. now owns 292,273 shares of the company's stock valued at $1,169,000 after buying an additional 4,685 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in AC Immune in the fourth quarter valued at $730,000. Finally, Handelsbanken Fonder AB acquired a new stake in AC Immune in the first quarter valued at $404,000. 26.49% of the stock is currently owned by institutional investors and hedge funds.AC Immune Company Profile (Get Rating)AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases